Design and synthesis of novel annulated thienopyrimidines as phosphodiesterase 5 (PDE5) inhibitors
- 14 April 2018
- journal article
- research article
- Published by Wiley in Archiv der Pharmazie
- Vol. 351 (5) , e1800018
Abstract
Novel cycloalkene‐fused thienopyrimidine analogues with enhanced phosphodiesterase 5 (PDE5) inhibitory properties are presented. The structure of the reported scaffold was modulated through variation of the terminal cycloalkene ring size, as well as by varying the substituents at position 4 through the attachment of different groups including aniline, benzylamine, cyclohexylethylamine, methyl/acetyl/aryl piperazines, and aryl hydrazones. Compound 15Y with a benzylamine substituent and cycloheptene as terminal ring showed the highest PDE5 inhibitory activity with an IC50 value as low as 190 nM and with good selectivity versus PDE7 and PDE9.Keywords
Funding Information
- National Cancer Institute (NCI 5 R01 CA155638)
This publication has 26 references indexed in Scilit:
- Thieno[2,3-d]pyrimidinedione derivatives as antibacterial agentsEuropean Journal of Medicinal Chemistry, 2012
- Effect of novel synthetic evodiamine analogue on sexual behavior in male ratsJournal of Chemical Biology, 2011
- Mammalian Cyclic Nucleotide Phosphodiesterases: Molecular Mechanisms and Physiological FunctionsPhysiological Reviews, 2011
- Synthesis and screening of some novel fused thiophene and thienopyrimidine derivatives for anti-avian influenza virus (H5N1) activityEuropean Journal of Medicinal Chemistry, 2010
- Design and Synthesis of Tetrahydropyridothieno[2,3-d]pyrimidine Scaffold Based Epidermal Growth Factor Receptor (EGFR) Kinase Inhibitors: The Role of Side Chain Chirality and Michael Acceptor Group for Maximal PotencyJournal of Medicinal Chemistry, 2010
- Phosphodiesterase inhibitors and the eyeClinical & Experimental Ophthalmology, 2009
- Oral Phosphodiesterase Type 5 Inhibitors: Nonerectogenic Beneficial UsesThe Journal of Sexual Medicine, 2008
- Synthesis of Some Thienopyrimidine DerivativesMolecules, 2006
- Identification and characterization of a new human type 9 cGMP-specific phosphodiesterase splice variant (PDE9A5)Gene, 2003
- Design, Synthesis, and Biological Activities of New Thieno[3,2-d]pyrimidines as Selective Type 4 Phosphodiesterase InhibitorsJournal of Medicinal Chemistry, 1998